February 11, 2021
AstraZeneca expects revenue to grow
AstraZeneca on Thursday said it expects its 2021 revenue to grow after its COVID-19 vaccine success topped previous estimates for fourth-quarter sales.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
February 11, 2021
Recipharm bolsters biologics offering
Global contract development and manufacturing organisation (CDMO), Recipharm, has successfully extended its manufacturing license to include immunology products, allowing them to cater for customers’ vaccine products at clinical and commercial scales, in both freeze-dried and liquid forms.
February 3, 2021
Abzena to to work on antibody cocktail for Immunome’s COVID-19 Antibody Based Treatment
Abzena announced they have been chosen to work with Immunome Inc. to produce IMM-BCP-01 for clinical testing – an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.
February 3, 2021
BMS sells its Swiss-based factory to WuXi STA
WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.
February 3, 2021
Carlyle and Brighton Park agree to invest US$200 million in Indegene
The Carlyle Group (NASDAQ: CG), Brighton Park Capital and Indegene, the Bangalore-headquartered enterprise healthtech solutions provider, today announced that Carlyle…
January 29, 2021
Marinomed Biotech ends 2020 with record increase in revenues
Marinomed Biotech has announced record preliminary revenues for 2020 and confirms its financial outlook after posting an increase in sales,…
January 28, 2021
Moderna confirms talking with the US on 100M doses of Cov-19 vaccine
After the US president’s Biden said the US Federal government would buy 100 million doses of the COVID-19 vaccine from Moderna and another 100 million from Pfizer, Moderna today confirmed that it is in discussion with the U.S. government to purchase an additional 100 million doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021.
January 28, 2021
CatalYm begins clinical development of CTL-002 to treat certain oncology patients
CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment.
January 27, 2021
Immunicum AB expanding its Netherlands R&D facilities in Leiden
Immunicum AB will move its in-house research and process development activities into a new facility at the Leiden Bio Science…
January 27, 2021
Teneobio cleared for it’s treatment of mCRPC in USA
Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific T-cell engaging antibody for the treatment of metastatic castrate resistant prostate cancer (mCRPC) was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on January 23, 2021.